Gilead Sciences (GILD) EBITDA (2009 - 2026)

Gilead Sciences has reported EBITDA for 18 years, with the latest figure at $2.6 billion in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 15.6% year-over-year to $2.6 billion; the trailing twelve-month figure through Mar 2026 stood at $10.4 billion (up 26.15% YoY), and the FY2025 full-year result was $10.0 billion, up 503.01% from the prior year.
• EBITDA for Q1 2026 stood at $2.6 billion, up from $2.0 billion in the prior quarter.
• The five-year high for EBITDA was $3.3 billion in Q3 2025, with the low at -$4.3 billion in Q1 2024.
• Historically, EBITDA has averaged $1.7 billion across 5 years, with a median of $2.2 billion in 2025.
• Annual changes were most pronounced in 2023 — EBITDA soared 765.48% — and 2024, when it plunged 353.49%.
• Gilead Sciences' EBITDA stood at $2.3 billion in 2022, then slipped by 28.89% to $1.6 billion in 2023, then soared by 52.11% to $2.5 billion in 2024, then fell by 19.09% to $2.0 billion in 2025, then jumped by 30.34% to $2.6 billion in 2026.
• The last three EBITDA figures came in at $2.6 billion (Q1 2026), $2.0 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.